Alicia C. Smart
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alicia C. Smart has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Anthony L. Zietman
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
2 shared publicationsDaphne A. Haas-Kogan
Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
2 shared publicationsM Aiven Dyer
Department of Radiation Oncology, Brigham and Women’s Hospital, Boston, MA, United States
2 shared publications- Mutlay Sayan
Department of Radiation Oncology, Brigham and Women’s Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
2 shared publications - Yetkin Tuac
Department of Statistics, Ankara University, Ankara 06100, Türkiye
2 shared publications Abigail M. Kempf
Department of Radiation Oncology, Brigham and Women’s Hospital, Boston, MA, United States
1 shared publication
Latest Publications
- Open Access
- 15 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4637
Association Between Cribriform Architecture and Tertiary Gleason Pattern 5 in Prostate Cancer: A Cross-Sectional Study of Radical Prostatectomy Specimens
Background/Objectives: Cribriform architecture is an adverse Gleason pattern 4 morphology associated with aggressive prostate cancer outcomes. Tertiary Gleason pattern 5, even as a minor component, may also identify tumors with higher-grade biology not fully captured by conventional Grade Group assignment. We examined whether cribriform architecture is associated with tertiary Gleason pattern 5 in patients undergoing radical prostatectomy. Methods: We performed a retrospective cross-sectional study of radical prostatectomy specimens from patients with prostate adenocarcinoma who underwent radical prostatectomy and had available clinicopathologic data. A centralized pathology review of digitized radical prostatectomy slides was used to assess cribriform architecture. Tertiary Gleason pattern 5 status was obtained from original pathology reports. Multivariable logistic regression was used to evaluate the association between cribriform architecture and tertiary Gleason pattern 5 after adjustment for age, preoperative prostate-specific antigen level, prostatectomy Gleason score, pathologic tumor stage, and margin status. Results: Among 303 patients, 47 (15.5%) had tertiary Gleason pattern 5. Cribriform architecture was more common in tumors with tertiary Gleason pattern 5 than in those without (70% vs. 21%; p < 0.001). On multivariable analysis, cribriform architecture remained independently associated with tertiary Gleason pattern 5 (adjusted odds ratio of 9.46; 95% confidence interval of 4.49–21.0; p < 0.001). The model demonstrated good discrimination, with an area under the receiver operating characteristic curve of 0.80. Conclusions: Cribriform architecture was strongly associated with tertiary Gleason pattern 5. These findings suggest that cribriform-positive tumors may be more likely to harbor minor high-grade pattern 5 components.
- 15 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4637
Open AccessAssociation Between Cribriform Architecture and Tertiary Gleason Pattern 5 in Prostate Cancer: A Cross-Sectional Study of Radical Prostatectomy Specimens
Background/Objectives: Cribriform architecture is an adverse Gleason pattern 4 morphology associated with aggressive prostate cancer outcomes. Tertiary Gleason pattern 5, even as a minor component, may also identify tumors with higher-grade biology not fully captured by conventional Grade Group assignment. We examined whether cribriform architecture is associated with tertiary Gleason pattern 5 in patients undergoing radical prostatectomy. Methods: We performed a retrospective cross-sectional study of radical prostatectomy specimens from patients with prostate adenocarcinoma who underwent radical prostatectomy and had available clinicopathologic data. A centralized pathology review of digitized radical prostatectomy slides was used to assess cribriform architecture. Tertiary Gleason pattern 5 status was obtained from original pathology reports. Multivariable logistic regression was used to evaluate the association between cribriform architecture and tertiary Gleason pattern 5 after adjustment for age, preoperative prostate-specific antigen level, prostatectomy Gleason score, pathologic tumor stage, and margin status. Results: Among 303 patients, 47 (15.5%) had tertiary Gleason pattern 5. Cribriform architecture was more common in tumors with tertiary Gleason pattern 5 than in those without (70% vs. 21%; p < 0.001). On multivariable analysis, cribriform architecture remained independently associated with tertiary Gleason pattern 5 (adjusted odds ratio of 9.46; 95% confidence interval of 4.49–21.0; p < 0.001). The model demonstrated good discrimination, with an area under the receiver operating characteristic curve of 0.80. Conclusions: Cribriform architecture was strongly associated with tertiary Gleason pattern 5. These findings suggest that cribriform-positive tumors may be more likely to harbor minor high-grade pattern 5 components.
- 4 December 2025
- Published by Elsevier in Brachytherapy
- Vol. 25 (2) , 300-305
National patterns of brachytherapy boost use for intermediate- and high-risk prostate cancer: Bridging the gap between evidence and practice
- 4 December 2025
- Published by Elsevier in Brachytherapy
- Vol. 25 (2) , 300-305
National patterns of brachytherapy boost use for intermediate- and high-risk prostate cancer: Bridging the gap between evidence and practice
- Open Access
- 1 August 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (15) , e71124
Low Testosterone Level and Mortality Risk in Patients With Prostate Cancer: A Post‐Randomization Analysis
Background: A low serum testosterone can prolong the time needed for PSA to exceed normal and prompt a work‐up to rule out prostate cancer (PC), delaying diagnosis. We evaluated PC aggressiveness at diagnosis and PC‐specific and all‐cause mortality (PCSM, ACM)‐risk within comorbidity subgroups in patients with low versus normal testosterone. Methods: Between 2005 and 2015, 350 PSA‐screened patients with tumor (T) category1c‐4N0M0 unfavorable‐risk PC were enrolled in a randomized trial and comprised the study cohort. Fine and Gray and Cox multivariable regression analyses were used to evaluate PCSM and ACM risk, respectively, adjusting for age, known PC prognostic factors, randomized treatment arm, and the time‐dependent use of salvage androgen deprivation therapy. An interaction term between the Adult Comorbidity Evaluation‐27 defined comorbidity and low versus normal testosterone was included in the models to enable an assessment of PCSM and ACM risk within comorbidity subgroups in patients with low versus normal testosterone levels at randomization. Results: After a median follow up of 10.20 years, 89 of 350 patients died (25.43%) with 42 of 89 deaths (47.19%) from PC. In patients with no or minimal but not moderate to severe comorbidity, a significant association was observed between low compared to normal testosterone level at randomization and increased PCSM (AHR: 2.70 [95% CI: 1.27, 5.76], p = 0.01) and ACM risk (AHR: 1.90 [95% CI: 1.11, 3.26], p = 0.02). Conclusion: Unlike PSA, multiparametric MRI (mpMRI) images are not influenced by the serum testosterone level; therefore, evaluating whether PCSM can be reduced by incorporating mpMRI into PC‐screening in otherwise healthy men or transgender women with a low serum testosterone level should be considered. Trial Registration: The statisical code used to derive the results from the interaction model for this post randomization analysis can be found in the Supporting Information.
- 1 August 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (15) , e71124
Open AccessLow Testosterone Level and Mortality Risk in Patients With Prostate Cancer: A Post‐Randomization Analysis
Background: A low serum testosterone can prolong the time needed for PSA to exceed normal and prompt a work‐up to rule out prostate cancer (PC), delaying diagnosis. We evaluated PC aggressiveness at diagnosis and PC‐specific and all‐cause mortality (PCSM, ACM)‐risk within comorbidity subgroups in patients with low versus normal testosterone. Methods: Between 2005 and 2015, 350 PSA‐screened patients with tumor (T) category1c‐4N0M0 unfavorable‐risk PC were enrolled in a randomized trial and comprised the study cohort. Fine and Gray and Cox multivariable regression analyses were used to evaluate PCSM and ACM risk, respectively, adjusting for age, known PC prognostic factors, randomized treatment arm, and the time‐dependent use of salvage androgen deprivation therapy. An interaction term between the Adult Comorbidity Evaluation‐27 defined comorbidity and low versus normal testosterone was included in the models to enable an assessment of PCSM and ACM risk within comorbidity subgroups in patients with low versus normal testosterone levels at randomization. Results: After a median follow up of 10.20 years, 89 of 350 patients died (25.43%) with 42 of 89 deaths (47.19%) from PC. In patients with no or minimal but not moderate to severe comorbidity, a significant association was observed between low compared to normal testosterone level at randomization and increased PCSM (AHR: 2.70 [95% CI: 1.27, 5.76], p = 0.01) and ACM risk (AHR: 1.90 [95% CI: 1.11, 3.26], p = 0.02). Conclusion: Unlike PSA, multiparametric MRI (mpMRI) images are not influenced by the serum testosterone level; therefore, evaluating whether PCSM can be reduced by incorporating mpMRI into PC‐screening in otherwise healthy men or transgender women with a low serum testosterone level should be considered. Trial Registration: The statisical code used to derive the results from the interaction model for this post randomization analysis can be found in the Supporting Information.
- 1 June 2024
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 10 (6) , 699
Policy Priorities in Cancer Care for Transgender People
This Viewpoint calls for health care systems, oncologists, and staff to prioritize and adopt policies that are inclusive and respectful of transgender patients with cancer.
- 1 June 2024
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 10 (6) , 699
Policy Priorities in Cancer Care for Transgender People
This Viewpoint calls for health care systems, oncologists, and staff to prioritize and adopt policies that are inclusive and respectful of transgender patients with cancer.
- Open Access
- 6 February 2024
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 9 (5) , 101461
A Multi-Institutional Survey of Radiation Oncology Professionals’ Knowledge, Attitudes, and Practice Behaviors Toward Sexual and Gender Minority Patients With Cancer
- 6 February 2024
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 9 (5) , 101461
Open AccessA Multi-Institutional Survey of Radiation Oncology Professionals’ Knowledge, Attitudes, and Practice Behaviors Toward Sexual and Gender Minority Patients With Cancer
- Open Access
- 7 September 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1135400
Clinical outcomes of radiation therapy for transgender and gender-expansive people with cancer
Introduction: Approximately 1.6 million people in the US identify as transgender, many of whom undergo gender-affirming medical or surgical therapies. While transgender individuals are diagnosed with cancer at similar rates as those who are cisgender, the impacts of radiation therapy on outcomes of gender-affirming care in transgender, nonbinary, and gender-expansive people with cancer are understudied. We report on the experiences and outcomes of transgender and gender-expansive patients receiving radiation therapy for cancer treatment.Methods: This study is a multi-institutional retrospective review of patients evaluated from 2005-2019 identified as transgender or gender-expansive in the medical record and treated with radiation therapy.Results: We identified 23 patients who received radiation to 32 sites, including 12 (38%) to the brain, head, or neck, 8 (25%) to the thorax, and 7 (22%) to the pelvis. Seventeen patients (74%) received gender-affirming hormone therapy and 13 patients (57%) underwent gender-affirming surgery. Four patients had pelvic radiation before or after gender-affirming pelvic surgery, including two trans women who had pelvic radiation after vaginoplasty. Four patients had radiation to the chest or thorax and gender-affirming chest or breast surgery, including two trans men with breast cancer. Two pediatric patients developed hypopituitarism and hypogonadism secondary to radiation therapy and, as adults, changed their hormone replacement therapy to affirm their transgender identities.Discussion: Transgender people with cancer undergo radiation therapy for a wide range of cancers. Understanding their prior gender-affirming medical or surgical treatments and future gender affirmation goals may identify important considerations for their oncologic care.
- 7 September 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1135400
Open AccessClinical outcomes of radiation therapy for transgender and gender-expansive people with cancer
Introduction: Approximately 1.6 million people in the US identify as transgender, many of whom undergo gender-affirming medical or surgical therapies. While transgender individuals are diagnosed with cancer at similar rates as those who are cisgender, the impacts of radiation therapy on outcomes of gender-affirming care in transgender, nonbinary, and gender-expansive people with cancer are understudied. We report on the experiences and outcomes of transgender and gender-expansive patients receiving radiation therapy for cancer treatment.Methods: This study is a multi-institutional retrospective review of patients evaluated from 2005-2019 identified as transgender or gender-expansive in the medical record and treated with radiation therapy.Results: We identified 23 patients who received radiation to 32 sites, including 12 (38%) to the brain, head, or neck, 8 (25%) to the thorax, and 7 (22%) to the pelvis. Seventeen patients (74%) received gender-affirming hormone therapy and 13 patients (57%) underwent gender-affirming surgery. Four patients had pelvic radiation before or after gender-affirming pelvic surgery, including two trans women who had pelvic radiation after vaginoplasty. Four patients had radiation to the chest or thorax and gender-affirming chest or breast surgery, including two trans men with breast cancer. Two pediatric patients developed hypopituitarism and hypogonadism secondary to radiation therapy and, as adults, changed their hormone replacement therapy to affirm their transgender identities.Discussion: Transgender people with cancer undergo radiation therapy for a wide range of cancers. Understanding their prior gender-affirming medical or surgical treatments and future gender affirmation goals may identify important considerations for their oncologic care.
- 24 May 2023
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 117 (2) , 301-311
Gender-Affirming Surgery and Cancer: Considerations for Radiation Oncologists for Pelvic Radiation in Transfeminine Patients
- 24 May 2023
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 117 (2) , 301-311
Gender-Affirming Surgery and Cancer: Considerations for Radiation Oncologists for Pelvic Radiation in Transfeminine Patients
- 19 December 2019
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 27 (4) , 1130-1131
ASO Author Reflections: High-Dose Radiation Offers Local Control for Inoperable Intrahepatic Cholangiocarcinoma
- 19 December 2019
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 27 (4) , 1130-1131
ASO Author Reflections: High-Dose Radiation Offers Local Control for Inoperable Intrahepatic Cholangiocarcinoma